John Babich

Co-Founder, President and CSO, Ratio Therapeutics

Dr. John Babich earned his PhD in Radiopharmaceutical Chemistry from the Institute of Cancer Research at the University of London in 1994. His career in radiopharmaceutical sciences and nuclear medicine spans over 30 years across academic, clinical, and industry settings.

In academia, Dr. Babich held positions at Harvard Medical School and Weill Cornell Medical College. He served as a radiopharmaceutical chemist at Massachusetts General Hospital and as professor and chief of radiopharmaceutical sciences at NewYork-Presbyterian Hospital/Weill Cornell Medical College.

Dr. Babich's industry experience is extensive. He co-founded Molecular Insight Pharmaceuticals in 1998, serving as Chief Scientific Officer and President for 15 years. At Molecular Insight, he led research strategy, directed platform technology development, and oversaw the introduction of five novel compounds into clinical trials. These included imaging agents for cardiac ischemia, prostate cancer, and targeted radiotherapy compounds for neuroendocrine cancers and melanoma. He also led the translation of PSMA-targeted radioligands for imaging and therapy from bench to bedside.

In 2021, Dr. Babich co-founded Ratio Therapeutics, where he currently serves as President and Chief Scientific Officer. His research focuses on developing next generation radiolabeled small molecules for cancer imaging and therapy.

Throughout his career, Dr. Babich has made significant contributions to the field of radiopharmaceutical sciences. He has co-authored over 230 peer-reviewed papers and is an inventor on more than 50 patents.

Jeremie Calais

Associate Professor, Department of Molecular and Medical Pharmacology; Director, Theranostics Program, David Geffen School of Medicine at UCLA

Dr Jeremie Calais, MD, PhD, is a nuclear medicine physician specialized in cancer imaging and theranostics working at the University of California Los Angeles (UCLA) since 2016. He serves as the Director of the Theranostics and Clinical Research Programs of the Ahmanson Translational Theranostics Division and as an Associate Professor in the Department of Molecular and Medical Pharmacology at the David Geffen School of Medicine, University of California Los Angeles (UCLA).

Dr. Calais completed his training in France: he earned his medical degree at the University of Paris VII Diderot, completed his residency at the Henri Becquerel Cancer Center, University of Rouen and his Fellowship at the Xavier Bichat University Hospital in Paris. He also obtained his Master of Sciences (MSc) and doctorate in sciences (PhD) at the University of Paris-Saclay.

Dr. Jeremie Calais MD PhD has established a clinical Theranostics research program that combines academic investigator-initiated and industry sponsored studies using targeted radionuclide imaging and therapy. He is a certified principal investigator by the ACRP. His goal is to improve the outcome of patients with cancer through theranostic approaches and the application of knowledge gained from preclinical models and clinical studies.

Dr Calais is also an Associate Editor of The Journal of Nuclear Medicine, and a Faculty Board Member of multiple organizations and committees such as the Jonsson Comprehensive Cancer Center at UCLA, the Institute of Urologic Oncology at UCLA, the Physics and Biology in Medicine Graduate Program at UCLA, the Correlative Imaging Council (CIC) of the SNMMI, the Prostate Theranostics and Imaging Centre of Excellence (ProsTIC), Melbourne, the SWOG Cancer Research Network or the Oncidium Foundation, Belgium.

Ken Herrmann

Professor of Nuclear Medicine, Universitätsmedizin Essen, Universität Duisburg-Essen, Germany

Nuclear Medicine Physician based in Essen, Germany. A 100% believer in Theranostics.

Prof. Dr Herrmann is Professor of Nuclear Medicine at the Universitätsklinikum Essen, Essen, Germany and until recently acted as Adjunct Professor at the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA), Los Angeles, California, USA.

In 2011, he completed his residency in nuclear medicine at Klinikum rechts der Isar, Technische Universität München, Munich, Germany, focusing on his research entitled “In Vivo Proliferation Imaging with 3´deoxy-3´-[18F]Fluorothymidine PET in Oncology”. Following this, Prof. Dr Herrmann then went onto complete a fellowship at Hokkaido University, Hokkaido, Japan, and received an executive MBA degree from the University of Zürich, Zürich, Switzerland. From 2012 to 2016, he served as Vice Chair of the Department of Nuclear Medicine at Universitätsklinikum Würzburg, Würzburg, Germany. Until 2023, he served as Chair of the European Association of Nuclear Medicine (EANM) Oncology & Theranostics Committee.

Presently, he is Section Editor of The Journal of Nuclear Medicine and Cancer Imaging. He has also authored more 700 peer-reviewed articles.

Sherly Mosessian

Chief Scientific Officer, SOFIE

Dr. Mosessian earned her bachelor’s degree in Biochemistry, followed by her Ph.D from UCLA Department of Molecular, Medical Pharmacology, with publications in tumor signaling, molecular imaging targets and clinical trials of Position Emission Tomography (PET) tracers. Prior to joining SOFIE, she served as a Chief Administrative Officer at UCLA and oversaw the establishment of a robust pathway for translational of PET tracers from bench to clinic, along with current Good Manufacturing Process facility in support of PET radiopharmaceuticals production for research and clinical service. In her role as the Chief Scientific Officer of SOFIE, she formulates the strategic plan for quality, compliance, regulatory and scientific objectives of the organization, including leading the radiopharmaceutical diagnostic clinical development program.

moderator

Paulo Rosado de Castro

Medical Director, Perceptive

Dr. Rosado de Castro is part of the Scientific and Medical Services team at Invicro, focusing on Oncology. He is a radiologist and nuclear medicine physician with over 15 years of experience as a principal investigator in preclinical translational imaging and early to late-phase clinical trials. Dr. Rosado de Castro has received numerous grants and authored more than 60 peer-reviewed publications. He is has served as an advisor or co-advisor for several M.Sc. and Ph.D. students. Dr. Rosado de Castro pursued the Medical Scientist Training Program and earned his M.D./Ph.D. at the Federal University of Rio de Janeiro. He completed his Nuclear Medicine Residency at the National Cancer Institute of Brazil and his Radiology Residency at the Federal Hospital of Ipanema. He received his M.B.A. from the Federal Fluminense University and was later certified as an M.D. by the University of Lisbon.